Tukysa is a HER2-directed tyrosine kinase inhibitor approved in combination therapy that has demonstrated a significant overall survival benefit in patients with HER2-positive metastatic breast cancer—including those with brain metastases. Its ability to cross the blood-brain barrier and maintain efficacy makes it a critical advancement in treatment of HER2+ disease. Its favorable tolerability profile, and ability to be used post multiple HER2-targeted therapies make it a valuable option in the treatment landscape for HER2-positive metastatic breast cancer.

This product manufactured by Seagen (Seattle Genetics) is a HER2-directed kinase inhibitor, meaning it blocks HER2 and HER3 phosphorylation in vitro, inhibiting downstream MAPK and AKT signaling, and reducing cell proliferation. It has shown anti-tumor activity in HER2-expressing cells. In vivo, tucatinib inhibited HER2-positive tumor growth. When combined with trastuzumab, tucatinib demonstrated enhanced anti-tumor effects in both in vitro and in vivo models compared to either agent alone.

Recommended dosage is 300 mg, orally, twice daily with or without food; and for patients with severe hepatic impairment is 200 mg orally twice daily. 

Some of the clinically significant adverse reactions include diarrhea, embryo fetal toxicity  and hepatotoxicity. 

Pricing and availability: 

Tucatinib (Tukysa) is prescribed for patients with HER2- positive metastatic breast cancer. However, tucatinib is not registered in India and is not readily available through local pharmacies or standard distribution networks.

Since this is a prescription-only therapy, the price quotation for tucatinib is provided upon request, after submission of valid medical documents. For updated pricing and procurement details, contact us. 

The price of tucatinib in India may vary depending on market dynamics, supplier availability, and regulatory updates, since the drug is not registered for commercial sale in India. Cost also depends on supplier, origin country, shipping and documentation. For the most accurate and updated pricing in India, patients can contact us directly.
Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies.

We help patients buy tucatinib India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Access: 

As tucatinib is not commercially registered in India, it can only be accessed through the Named Patient Import Program (NPIP). We assist patients with products like tucatinib in India by procuring medicines for patients under the Named Patient Supply (NPS) route.

Tukysa or tucatinib is supplied as 50 mg or 150 mg tablets with 60 counts in each of 75 cc bottles or 150 mg tablets as 120 counts in each of 150 cc bottles. 

Import process:

1. Request submission for your medicine
   Patients or caregivers can send a request for the product by sharing prescription details and treatment requirements.
2. Submission of an application (Form 12A)
   Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
3. Verification of documents
   We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
4. Permission to import
   Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
5. Sourcing the medicine
   Our sourcing team connects with authorized global suppliers to find the best anakinra price in India, thus making it convenient to easily import tucatinib in India, and ensure authenticity before finalizing the offer.
6. Delivery of the medicine
   After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of the product to the patient’s location in India.

Documents Require: 

To enable the product’s import to India, patients need to provide:

1. A valid doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
2. Recent medical history and test reports (preferably from the last three months), including those confirming disease. 
3. Government-issued ID proof and proof of residence of the patient.
4. Import permit if applicable.
   

Order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Tukysa from the USA, Canada, Europe, or Australia, etc. 
With these steps, patients can import tucatinib India safely and legally. We make the medicines available in major Indian cities and source only from genuine international suppliers to ensure safety and authenticity. We ensure 100% transparency in pricing and supply is guaranteed. Prescriptions are dispensed and checked by registered pharmacists before delivery to patients.